This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Ng R, Hasan B, Mittmann N, Florescu M, Shepherd FA, Ding K, Butts CA, Cormier Y, Darling G, Goss GD, Inculet R, Seymour L, Winton TL, Evans WK, Leighl NB.Economic analysis of NCIC CTG JBR.10: a randomized trial of adjuvant vinorelbine plus cisplatin compared with observation in early stage non-small-cell lung cancer - a report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Groups. Journal of Clinical Oncology 25: 2256-2261, No. 16, 1 Jun 2007
Rights and permissions
About this article
Cite this article
ICER favours vinorelbine + cisplatin for NSCLC. Pharmacoecon. Outcomes News 534, 5 (2007). https://doi.org/10.2165/00151234-200705340-00010
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200705340-00010